Cloud DX Signs Contract with US University Nursing School

Cloud DX supplies Virtual Care and Remote Patient Monitoring hardware and services to educate the next generation of nurses and nurse practitioners in Oregon

News in Summary

Cloud DX has signed an 18 month contract with University School of Nursing in Oregon
Company to supply its Connected Health™ hardware, services, and connectivity to educate nursing students on best-in-class virtual care systems
This is the ninth contract executed or deployed in Q1 2022 for Cloud DX

KITCHENER, ON / ACCESSWIRE / March 8,2022 /Cloud DX (TSXV:CDX) (OTC:CDXFF), Cloud DX, a leading Virtual Care platform, announces today the signing of an 18 month contract as the exclusive vendor for Telemedicine and Remote Patient Monitoring equipment, services, and connectivity with a University Nursing School in Portland, Oregon.

This agreement demonstrates key competitive advantages of the company's Connected Health™ offering: including easy-to-use medical devices, intuitive and flexible user interfaces, and exceedingly high user satisfaction. Two hospitals using Cloud DX platform, The Ottawa Hospital and Kingston Health Science Center, released results of recent user surveys. Each indicated that over 95% of users were satisfied or very satisfied with Connected Health™.

"Patients love our Connected Health platform and Healthcare educators do too," says Robert Kaul, CEO and Founder of Cloud DX. "Our platform lowers the burden on healthcare staff and enables nurses to be closer and more connected to their patients. With a closer circle of care, our virtual care and remote monitoring solutions improve patient outcomes, in turn reducing hospital re-admissions and lowering system costs. Agreements such as this one ensure upcoming generations of nursing students are learning to leverage Telemedicine and Remote Patient Monitoring to make healthcare better, for everyone, the Cloud DX way."

About Cloud DX

Accelerating virtual healthcare, Cloud DX is on a mission to make healthcare better for everyone. Our Connected Health^TM remote patient monitoring platform is used by healthcare enterprises and care teams across North America to virtually manage chronic disease, enable aging in place, and deliver hospital-quality post-surgical care in the home. Our partners achieve better healthcare and patient outcomes, reduce the need for hospitalization or re-admission, and reduce healthcare delivery costs through more efficient use of resources. Cloud DX is the co-winner of the Qualcomm Tricorder XPRIZE, a 2021 Edison Award winner, a Fast Company "World Changing Idea" finalist, and one of "Canada's Ten Most Prominent Telehealth Providers." In 2021, Cloud DX became an exclusive partner to Medtronic Canada.

Cloud DX Investor Site:https://ir.clouddx.com/overview/default.aspx

^{Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.}

Social Links

Twitter https://twitter.com/CloudDX
Facebook https://www.facebook.com/clouddxinc/
LinkedIn https://www.linkedin.com/company/cloud-dx/
Instagram https://www.instagram.com/cloud.dx/

For media inquiries please contact:

Janine Scott
Marketing Lead
888-543-0944
janine.scott@CloudDX.com

For investor inquiries please contact:

Jay Bedard
Cloud DX Investor Relations
647-881-8418
jay.bedard@CloudDX.com

SOURCE:Cloud DX Inc.

View source version on accesswire.com:
https://www.accesswire.com/692054/Cloud-DX-Signs-Contract-with-US-University-Nursing-School

News Provided by ACCESSWIRE via QuoteMedia

Cloud DX TSXV:CDX Emerging Tech Investing

CDX:CA

Sona's Cancer Therapy Triggers Abscopal Effect, Eliminating Distant Tumors In Preclinical Melanoma Study

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce that a detailed biomarker analysis of the recently reported pre-clinical melanoma study conducted at Dalhousie University (the "Study") indicates that, beyond shrinking tumors on its own, Sona's Targeted Hyperthermia Therapy ("THT") also stimulates the innate immune system to target and eliminate untreated (contralateral) tumors when combined with a standard immunotherapeutic drug, IL-2. (See figure #1, below.) On the basis of efficacy data achieved in two different murine cancer models (triple negative breast cancer and malignant melanoma), the Company is now proceeding with safety and biocompatibility testing that will be required by regulating agencies to enter into human studies.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

PRINCIPAL TECHNOLOGIES ANNOUNCES CLOSING OF FIRST TRANCHE OF PRIVATE PLACEMENT

Principal Technologies Inc. (the " Company ") (TSXV: PTEC) (FSE: J07), is pleased to announce the closing of the first tranche (" Tranche 1 ") of its previously announced non-brokered private placement (the " Offering ") with one investor, MRPT Invest UG (" MRPT "), a company owned and controlled by Markus Mair . The Company issued a total of 4,000,000 units at $0.25 per unit for gross proceeds of $1,000,000 . Each unit (a " Unit ") will consist of one common share (a ' Share ") of the Company and one common share purchase warrant (a " Warrant "). Each Warrant entitles the holder to purchase one additional Share of the Company at $0.30 for a period of two (2) years from the date of closing. The Warrants are subject to a blocker term that prohibits exercise of the Warrants to the extent the holder would as a result of any exercise exceed 19.99% of then issued Shares.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Sona's Therapy Shows Significant Preclinical Efficacy in Second Cancer

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce that its targeted hyperthermia therapy ("THT") demonstrated positive results in a second preclinical cancer model. Findings just presented at the 2024 STING & TLR Targeted Therapies Summit for immunotherapies in San Diego, California, show that Sona's THT achieved responses in a preclinical melanoma model equal to that which was recently reported from its triple negative breast cancer study. THT effectively treated melanoma tumors in all animals when administered on its own. Further, when THT was combined with doses of interleukin-2 ("IL-2"), a standard immunotherapy, a synergistic effect was shown whereby greater treatment response, measured by tumor volume reduction, was achieved in comparison to either approach alone.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Cloud DX Signs Contract with US University Nursing School

Latest News

Latest Press Releases

Related News

TOP STOCKS